MSL
TVTX icon

Mackay Shields LLC’s Travere Therapeutics TVTX Stock Holding History

Mackay Shields LLC’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-41,927
Closed -$1.05M – 1289
2021
Q1 		$1.05M Sell
41,927
-31,173
-43% -$861K 0.01% 981
2020
Q4 		$1.99M Buy
73,100
+9,800
+15% +$229K 0.01% 856
2020
Q3 		$1.17M Sell
63,300
-18,000
-22% -$350K 0.01% 980
2020
Q2 		$1.66M Buy
81,300
+12,600
+18% +$201K 0.01% 841
2020
Q1 		$1M Sell
68,700
-11,800
-15% -$178K 0.01% 945
2019
Q4 		$1.14M Buy
80,500
+4,300
+6% +$54.9K 0.01% 1043
2019
Q3 		$883K Buy
76,200
+300
+0.4% +$4.96K 0.01% 1143
2019
Q2 		$1.52M Buy
75,900
+50,273
+196% +$993K 0.01% 1004
2019
Q1 		$580K Buy
25,627
+4,700
+22% +$104K ﹤0.01% 1147
2018
Q4 		$473K Sell
20,927
-2,173
-9% -$54.1K ﹤0.01% 1155
2018
Q3 		$664K Buy
23,100
+4,100
+22% +$117K 0.01% 961
2018
Q2 		$518K Buy
+19,000
New +$506K ﹤0.01% 1097

Other funds holding TVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Mackay Shields LLC's TVTX Position: Q2 2021 in Review

Mackay Shields LLC sold out of Travere Therapeutics (TVTX) in Q2 2021, closing a stake of 41,927 shares — an estimated $1.05M sold.

Mackay Shields LLC first reported a position in TVTX in Q2 2018 and held it in 12 quarters. The position peaked at $1.99M in Q4 2020. 136 funds tracked by Wall St. Rank hold TVTX as of Q2 2021.

  • Mackay Shields LLC reported no remaining Travere Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 41,927 Travere Therapeutics shares in Q2 2021, an estimated $1.05M.
  • Mackay Shields LLC first reported a position in Travere Therapeutics in Q2 2018 and held it in 12 quarters.
  • Mackay Shields LLC's Travere Therapeutics position peaked at $1.99M in Q4 2020.
  • 136 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.